Top Markets
Coin of the day
Hancock Jaffe Laboratories Hancock Jaffe Laboratories

Hancock Jaffe Laboratories

HJLI
株式のランク #35033
Hancock Jaffe Laboratories, Inc. is a medical device company in its... Hancock Jaffe Laboratories, Inc. is a medical device company in its developmental stage, specializing in creating advanced tissue-based and biologic solutions. These innovations are engineered to either sustain or significantly enhance the lives of patients afflicted with cardiovascular, peripheral arterial, and venous diseases, as well as end-stage renal disease (ESRD). The firm, headquartered in Irvine, California, maintains a dedicated team of nine full-time employees. Among its key initiatives, the company is actively developing implantable bioprosthetic devices for cardiovascular applications. This includes the Bioprosthetic Heart Valve (BHV), a swine-derived heart valve designed to mimic the function of a native heart valve and provide superior performance compared to current prosthetic options. Furthermore, the company is developing a Venous Valve, another bioprosthetic device sourced from pig tissue. This valve is specifically designed for individuals suffering from chronic venous insufficiency (CVI) in the lower limbs, a condition frequently resulting from damage to leg vein valves after the formation of deep venous blood clots.
株価
$10.38
最終同期: 2021-09-30
時価総額
$4.55M
変化(1日)
-1.98%
変化(1年)
0.00%
US
取引 Hancock Jaffe Laboratories (HJLI)

カテゴリー

Hancock Jaffe Laboratories(HJLI)の利益
2026 時点の利益 TTM: 0
Hancock Jaffe Laboratories の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Hancock Jaffe Laboratories の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益